<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332022000100008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Incidencia del carcinoma de células renales en Santiago de Cuba]]></article-title>
<article-title xml:lang="en"><![CDATA[Incidence of renal cell carcinoma in Santiago de Cuba]]></article-title>
<article-title xml:lang="pt"><![CDATA[Incidência de carcinoma de células renais em Santiago de Cuba]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Cruzata]]></surname>
<given-names><![CDATA[Lesyibeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Orlando Pantoja Tamayo&#8221;  ]]></institution>
<addr-line><![CDATA[ Santiago de Cuba,]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<volume>101</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332022000100008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332022000100008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332022000100008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Los tumores del parénquima renal representan aproximadamente del 2-3 % de los tumores del adulto y el 85 % de los tumores primarios del riñón. Se observa una incidencia aumentada de tumores del parénquima renal de forma variable en el mundo y en Cuba en los últimos años. Es en todo el mundo el cáncer más mortal de las vías urinarias.  Objetivo:  Identificar la incidencia y características clínico-epidemiológicas e histopatológicas del carcinoma de células renales en la provincia de Santiago de Cuba.  Método: Se realizó un estudio descriptivo y transversal sobre el adenocarcinoma renal en la provincia de Santiago de Cuba, en una serie de 88 pacientes desde el 1ro. de enero de 2012 a 1ro. de enero de 2017. El diagnóstico se fundamentó en los estudios histopatológicos de los pacientes intervenidos quirúrgicamente y fallecidos por esta enfermedad. Se estudiaron las variables: incidencia, edad, sexo, factores de riesgo, síntomas y signos, tipo histológico y estadificación.  Resultados: Fue más frecuente entre la quinta y sexta décadas de la vida y en el sexo masculino. El tabaquismo fue el principal factor de riesgo. Más del 50 % de los casos fue diagnosticado de forma incidental y asintomática, aunque aparecieron síntomas como el dolor en flanco, hematuria, síntomas generales y masa abdominal palpable. El tumor de células claras resultó la variedad histológica que más afectó. Se diagnosticaron principalmente en estadio T3a.  Conclusiones: Médicos de familia, clínicos, urólogos y radiólogos participan en el diagnóstico del carcinoma renal, por lo que es importante que se tenga en cuenta esta entidad ya que se pude presentar de la manera más insospechada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Renal parenchymal tumors account for approximately 2-3% of tumors in adults&#8217; patients and in turn the 85% of primary kidney tumors. An increased incidence of renal parenchymal tumors has been observed around the world and in Cuba in the last years. It is the most deadly cancer in the urinary tract worldwide.  Objective:  To identify incidence and the clinical-epidemiological and histopathological features of renal cell carcinoma in the province of Santiago de Cuba.  Method:  A descriptive and cross-sectional study was conducted concerning renal adenocarcinoma in 88 patients from Santiago de Cuba. Period of study was from January 1, 2012 throughout January 1, 2017. The diagnosis was based on histopathological studies from patients who underwent surgery and died due to this disease. Variables studies were as follow: incidence, age, sex, risk factors, symptoms and signs, histologic type and cancer staging.  Results:  It was more frequent between the fifth and sixth decades of life and in males. Smoking was the main risk factor. More than 50 % of cases were diagnosed incidentally and asymptomatically, although symptoms such as flank pain, hematuria, general symptoms and palpable abdominal mass appeared. Clear cell tumor was the histologic variety most affected. They were diagnosed mainly in stage T3a.  Conclusions: Family physicians, clinicians, urologists and radiologists are involved in the diagnosis of renal carcinoma, so it is important to be aware of this illness since it can present in the most unsuspected way.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  Os tumores do parênquima renal representam aproximadamente 2-3% dos tumores adultos e 85% dos tumores renais primários. Um aumento da incidência de tumores do parênquima renal tem sido observado de forma variável no mundo e em Cuba nos últimos anos. É o câncer do trato urinário mais mortal em todo o mundo.  Objetivo:  Identificar a incidência e as características clínico-epidemiológicas e histopatológicas do carcinoma de células renais na província de Santiago de Cuba.  Método:  Foi realizado um estudo descritivo e transversal sobre adenocarcinoma renal na província de Santiago de Cuba, em uma série de 88 pacientes de 1º de janeiro de 2012 a 1º de janeiro de 2017. O diagnóstico foi baseado em estudos histopatológicos de pacientes que passou por uma cirurgia e morreu dessa doença. As variáveis estudadas foram: incidência, idade, sexo, fatores de risco, sintomas e sinais, tipo histológico e estadiamento.  Resultados:  Foi mais frequente entre a quinta e sexta décadas de vida e no sexo masculino. O tabagismo foi o principal fator de risco. Mais de 50% dos casos foram diagnosticados de forma incidental e assintomática, embora tenham surgido sintomas como dor no flanco, hematúria, sintomas gerais e massa abdominal palpável. O tumor de células claras foi a variedade histológica que mais acometia. Eles foram diagnosticados principalmente no estágio T3a.  Conclusões:  Médicos de família, clínicos, urologistas e radiologistas participam no diagnóstico do carcinoma renal, pelo que é importante ter em conta esta entidade, uma vez que pode apresentar-se da forma mais inesperada.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[adenocarcinoma]]></kwd>
<kwd lng="es"><![CDATA[riñón]]></kwd>
<kwd lng="es"><![CDATA[carcinoma de células renales]]></kwd>
<kwd lng="es"><![CDATA[incidencia]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico]]></kwd>
<kwd lng="en"><![CDATA[adenocarcinoma]]></kwd>
<kwd lng="en"><![CDATA[kidney]]></kwd>
<kwd lng="en"><![CDATA[renal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[incidence]]></kwd>
<kwd lng="en"><![CDATA[diagnosis]]></kwd>
<kwd lng="pt"><![CDATA[adenocarcinoma]]></kwd>
<kwd lng="pt"><![CDATA[rim]]></kwd>
<kwd lng="pt"><![CDATA[carcinoma de células renais]]></kwd>
<kwd lng="pt"><![CDATA[incidência]]></kwd>
<kwd lng="pt"><![CDATA[diagnóstico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campbell Steven]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lane Brian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores Renales Malignos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Wein Alan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Campbell-Walsh Urología]]></source>
<year>2015</year>
<volume>2</volume>
<edition>10ed</edition>
<page-range>1431-509</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[DF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo Vazquez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Santander Flores]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales Villegas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo López]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Yañes Sosa]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Reyna Blanco]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nefrectomía radical: incidencia de morbilidad y mortalidad en un hospital de tercer nivel]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2017</year>
<volume>77</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>446-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahdavifar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ghonchen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salehiniya]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, Mortality and risk factors of Kidney cancer in the world]]></article-title>
<source><![CDATA[World Cancer Res J]]></source>
<year>2018</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ljungberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Albiges]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abu-Ghanem]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bensalah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dabestani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Pello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2019</year>
<volume>75</volume>
<page-range>799-810</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Uzzo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Allaf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cadeddu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal mass and Localized renal cancer: AUA Guideline]]></article-title>
<source><![CDATA[Am Urol Assoc Educ Res]]></source>
<year>2017</year>
<page-range>1-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Lorenzo]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Reyes]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Rondón]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alvares-Sánchez]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Rodríguez]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de variables clínicas y terapéuticas en pacientes con adenocarcinoma de células renales claras]]></article-title>
<source><![CDATA[Rev Electrón Dr. Zoilo E. Marinello Vidaurreta]]></source>
<year>2018</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uscanga-Yépez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martnez-González]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia-Sandoval]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Barrera-Juárez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González-Oyervides]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manifestaciones clínicas y resultados oncológicos del cáncer renal en un hospital del norte de México]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2018</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>176-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer of the Kidney and Renal Pelvis - SEER Stat Fact Sheets]]></article-title>
<source><![CDATA[seer.cancer.gov]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>ONEI</collab>
<source><![CDATA[Anuario Estadístico de Santiago de Cuba 2016]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Santiago de Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Oficina Nacional de Estadísticas e Información]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montironi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Scarpelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Beltran]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathology and Genetics: The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2016</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93-105</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bolger]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Boston]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carducci]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fishman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Practice Guidelines in Oncology Kidney Cancer]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2006</year>
<volume>4</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1072-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ervik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dikshit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Incidence and Mortality Worldwide: sources, methods and major patterns in GLOBOCAN 2012]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2015</year>
<volume>136</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>E359-86</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Darias Martín]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Collar]]></surname>
<given-names><![CDATA[TL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influencia del estadio tumoral inicial en la sobrevida de pacientes con adenocarcinoma renal]]></article-title>
<source><![CDATA[Rev Cubana Med Mil]]></source>
<year>2018</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Román]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[García Morales]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enucleación simple en el tratamiento de los tumores renales]]></article-title>
<source><![CDATA[Rev Cubana Urol]]></source>
<year>2017</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk models for patients with localized renal cell carcinoma]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2017</year>
<volume>41</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>564-70</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gelfond]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>340.e1-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arteche]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<source><![CDATA[Epidemiología descriptiva y análisis de supervivencia del cáncer de riñón en los hospitales públicos de la Comunidad Autónoma de Madrid]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Complutense de Madrid, Facultad de Medicina]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inamura]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2017</year>
<volume>18</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorente]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Trilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meseguer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Planas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Placer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión sistemática de los factores pronósticos del carcinoma renal]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2017</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>215-25</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorente]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Trilla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meseguer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valor de la proteína STAT3c como factor pronóstico en el carcinoma renal de célula clara. Revisión sistemática]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2019</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>118-23</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clemmensen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathologic and clinical characteristics of early onset renal cell carcinoma]]></article-title>
<source><![CDATA[Human Pathology]]></source>
<year>2018</year>
<volume>74</volume>
<page-range>25-31</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alevizakos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gaitanidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nasioudis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Msaouel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Appleman]]></surname>
<given-names><![CDATA[LJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sarcomatoid renal cell carcinoma: population-based study of 879 patients]]></article-title>
<source><![CDATA[Clin Genitourin Cancer]]></source>
<year>2019</year>
<volume>17</volume>
<page-range>e447-53</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prokopowicz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nowakowski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bogacki]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bryniarski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Paradysz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma]]></article-title>
<source><![CDATA[Bio Med Res Int]]></source>
<year>2016</year>
<numero>8687575</numero>
<issue>8687575</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
